FDA Rejects Long-Acting Version of Copaxone by Viatris and Mapi Pharma

Monday, 11 March 2024, 13:43
The FDA has declined to approve the long-acting version of Teva's Copaxone developed by Viatris and Mapi Pharma. This decision has implications for the MS drug market and the future of glatiramer acetate therapies. Financial stakeholders are closely watching the developments following this significant setback.
https://store.livarava.com/8cbc86f6-e02c-11ee-9662-5254a2021b2b.jpe
FDA Rejects Long-Acting Version of Copaxone by Viatris and Mapi Pharma

FDA Rejects Long-Acting Version of Copaxone

Viatris (VTRS) announced that the FDA has declined to approve the long-acting version of Copaxone, a key drug in the MS treatment landscape. Mapi Pharma's collaboration with Viatris on this product faced a setback with this decision. The MS community is eagerly awaiting further updates on the status of this innovative therapy.

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe